Consumption of oral anticoagulants in hospitals of the Russian Federation: analysis of the dynamics of procurement data
- Authors: Matveev A.V.1, Glagoleva S.V.1, Sychev D.A.1
-
Affiliations:
- Medical Academy of Continuous Professional Education
- Issue: Vol 30, No 12 (2023)
- Pages: 98-106
- Section: Original articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/626057
- DOI: https://doi.org/10.18565/pharmateca.2023.12.98-106
- ID: 626057
Cite item
Open Access
Access granted
Abstract
Background. Thromboembolic complications are the one the factors that plays a significant role in the increase in mortality and disability of the population. The main role in their treatment and prevention belongs to anticoagulants; incl. oral anticoagulants (OACs); which include rivaroxaban; apixaban and dabigatran. OACs have gained particular importance in the context of the novel coronavirus infection (COVID-19) pandemic.
Objective. Evaluation of the consumption of OACs in hospitals in the Russian Federation for the period from 2017 to 2022 and the characteristics of their consumption during the COVID-19 pandemic.
Methods. The database of OOO Cursor Marketing LLC was used as a data source. Data on contracts concluded between 01/01/2017 and 12/31/2022 were analyzed. Data published by WHO from March 1; 2020 to December 31; 2022 were used as a source of data on morbidity and mortality from COVID-19. Consumption was calculated based on DDD (Defined Daily Dose) data presented on the WHO Collaborating Center website.
Results. Total for the period 2017–2022. 57;866 records were entered into the Cursor databases; of which 47.38% of records contained an indication that the purchased drug was rivaroxaban; 26.51% – dabigatran and 26.11% – apixaban. There was a drop in the number of contracts in 2022; from 2017 to 2021; their number grew; with the increase being more pronounced for apixaban and the least significant for dabigatran. Similar dynamics were observed for the volume of contracts; expressed in the number of packages and DDD; 97% of all contracts were concluded for a period of one year. For all analyzed time series; the presence of seasonality was found. The number of packages purchased and the DDD of rivaroxaban (P<0.05) and apixaban (P<0.001) purchased were correlated with rates of new illness and death from COVID-19.
Conclusion. The problem of studying the dynamics of OAC consumption is of significant practical interest. The number of requests for the purchase of OACs in Russian hospitals is increasing; and the COVID-19 pandemic has had a significant impact on the procurement structure.
Keywords
Full Text
About the authors
Aleksandr V. Matveev
Medical Academy of Continuous Professional Education
Author for correspondence.
Email: matveevav@rmapo.ru
ORCID iD: 0000-0002-6636-3950
SPIN-code: 8518-1320
Scopus Author ID: 37088844200
ResearcherId: 6168-2019
Cand. Sci. (Med.), Associate Professor at the Department of Clinical Pharmacology and Therapy n.a. acad. B.E. Votchaln
Russian Federation, MoscowS. V. Glagoleva
Medical Academy of Continuous Professional Education
Email: matveevav@rmapo.ru
Scopus Author ID: 57193931109
Department of Clinical Pharmacology and Therapy n.a. Acad. B.E. Votchaln
Russian Federation, Moscow
D. A. Sychev
Medical Academy of Continuous Professional Education
Email: matveevav@rmapo.ru
ORCID iD: 0000-0002-4496-3680
SPIN-code: 4525-7556
Scopus Author ID: 7801389135
ResearcherId: 6422-2018
Department of Clinical Pharmacology and Therapy n.a. Acad. B.E. Votchaln
Russian Federation, MoscowReferences
- Strom B.L.; Kimmel S.E.; Hennessy S.; eds. Pharmacoepidemiology. Wiley; 2012. doi: 10.1002/9781119959946.
- WHO International Working Group for Drug Statistics Methodology; WHO Collaborating Centre for Drug Statistics Methodology; WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacology. Introduction to Drug Utilization Research. WHO; 2003. Accessed October 3; 2023. URL: https://www.who.int/publications/i/item/8280820396
- Чеберда А.Е. Исследования потребления лекарственных средств. Качественная клиническая практика. 2017;(1):42–5. [Cheberda A.E. Drug utilization studies. Quality Clin Pract. 2017;(1):42–5. (In Russ.)].
- Whitworth M.M.; Haase K.K.; Fike D.S.; et al. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017;10:87. doi: 10.2147/IJGM.S129235.
- Dobesh P.P. Economic Burden of Venous Thromboembolism in Hospitalized Patients. Pharmacother. 2009;29(8):943–53. doi: 10.1592/phco.29.8.943.
- Lim G.B. Milestone 2: Warfarin: from rat poison to clinical use. Nature Publishing Group. Published on-line 2017. doi: 10.1038/nrcardio.2017.172.
- Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов; получающих оральные антикоагулянты. Терапия. 2021;10(51):23–41. [Expert consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy. 2021;10(51):23–41. (In Russ.)].
- Временные методические рекомендации. Профилактика; диагностика и лечение новой коронавирусной инфекции (COVID-19). 8th ed. Министерство здравоохранения Российской Федерации; 2020. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf. [Temporary methodological recommendations. Prevention; Diagnosis and Treatment of Emerging Coronavirus Infection (COVID-19). 8th ed. Ministry of Health of the Russian Federation; 2020. (In Russ.)].URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf
- Клейменова Е.; Отделенов В.; Нигматкулова М. и др. Динамика применения антикоагулянтов в многопрофильном стационаре в 2008–2018 гг. Рациональная фармакотерапия в кардиологии. 2021;17(4):544–51. [Kleymenova E.; Otdelenov V.; Nigmatkulova M.; et al. Dynamics of anticoagulant use in a multidisciplinary hospital in 2008–2018. Rational Pharmacoth Cardiol. 2021;17(4):544–51. (In Russ.)]. doi: 10.20996/1819-6446-2021-08-10.
- Yan V.K.C.; Li H.L.; Wei L.; et al. Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019. Drugs. 2023;83(4):315–40. doi: 10.1007/s40265-023-01837-0.
- Navar M.; Kolkailah A.A.; Overton R.; et al. Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice; 2011 to 2020. J Am Heart Associat.: Cardiovasc. Cerebrovasc. Dis. 2022;11(22):26723. doi: 10.1161/JAHA.122.026723.
- Ho K.H.; van Hove M.; Leng G. Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC. Health Serv Res. 2020;20(1):279. doi: 10.1186/s12913-020-5058-1.
- Alkhameys S.; Barrett R. Impact of the COVID-19 pandemic on England’s national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019–February 2021). Curr Med Res Opin. 2022;38(7):1081–92. doi: 10.1080/03007995.2022.2078100.
- Antonazzo I.C.; Fornari C.; Paoletti O.; et al. COVID-19 Outbreak Impact on Anticoagulants Utilization: An Interrupted Time-Series Analysis Using Health Care Administrative Databases. Thromb Haemost. 2021;121(08):1115–18. doi: 10.1055/a-1523-7658.
- Baybulatova E.A.; Chenkurov M.S.; Korovyako-va E.A.; et al. Direct Oral Anticoagulants Consumption and Expenditure in Covid-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use. Published online 2023. doi: 10.20944/preprints202311.0254.v1.
- DSM Group. Фармацевтический рынок России – 2022 г. 2023. Accessed November 15; 2023. URL: https://dsm.ru/docs/analytics/Annual_report_2023_rus.pdf. [DSM Group. Pharmaceutical Market in Russia – 2022. 2023. Accessed November 15; 2023. (In Russ.)].URL: https://dsm.ru/docs/analytics/Annual_report_2023_rus.pdf
Supplementary files
